Abstract:Objective Although it had been shown that mild or moderate hypothermia is safe in treatment of neonatal hopoxic-ischemic encephalopathy (HIE) in small scaled pilot clinical study, it is necessary to make multicentre randomized controlled trial to verify its efficacy in neonates with HIE. This multicentre randomized trial was to study the safety of selective head cooling (SHC) with mild systemic hypothermia in neonates with HIE. Methods Infants were qualified for the study if they were ≥36of weeks gestation,≥2 500 g of birth weight,and ≤6 h after birth. Cord blood gas pH ≤7. 0 or base deficit≥16 mmol ·L-1,or Apgar score ≤3 at 1 min, continued≤5 at 5 min. Neurological findings of neonatal encephalopathy included lethargy, stupor, or coma, with one or more of hypotonia, abnormal reflexes, absent or weak suck or clinical seizures. Exclusion criteria included:major congenital abnormalities, head trauma causing major intracranial hemorrhage, infection or severe anemia.Two hundred and forty-six term infants from 16 tertiary referral hospitals with various severity of neonatal encephalopathy were randomly assigned to either head cooling (n=134) or control group (n=112). In 29 babies follow up was not available (17 in cooling and 12 in control respectively). Thus 217 allocated to head cooling (n=117) and control group (n=100) respectively. In head cooling group,the nasopharyngeal temperature was maintained at (34±0. 2)℃ and rectal temperature maintained at 34 -35℃ for 72 h,then rewarmed spontaneously. In control group,normal rectal temperature was maintained. During study period,the babies in both groups were given mornitoring of nasopharyngeal temperature, heart rate, respiration rate, transcutaneous arterial oxygen saturation and blood pressure. Severe adverse events were recorded which included death, major cardiac arrhythmia, major venous thrombosis or hemorrhage and severe hypotension despite full support. Na+,K+,Ca2+,glucose, GPT,GOT,BUN,Cr,pH and BE were measured at 72h after treatment. Results The case-fatality rate was not significantly different in both groups(17.9% in cooling vs 25% in control group,P=0.20). The major cause of death was severe HIE (6. 8% in cooling vs 7% in control group,P = 0. 96) and respiratory failure (6. 8% in cooling vs 6% in control group respectively,P=0. 80) . There was one neonate with ventricular arrhythmia and DIC in control group and two neonates with DIC and severe gastrointestinal hemorrhage respectively in SHC group. The rate of severe adverse events was not signicantly different in both groups (1.7% in cooling vs 2% in control group, P = 1.00). In SHC group,most neonates had lower heart rates during the period of hypothermia,but HR below 80 beats/min was observed in only 4 cases (3.4%) . The systolic and diastolic blood pressures were stable,and no difference were found between SHC and control group. The rate of abnormal renal function, elevated liver enzyme activities, metabolic acidosis, hypoglycemia, hyperglycemia, hypocalcaemia, hyponatraemia, and hyperkalaemia were not significantly different between two groups. The average values of white blood cells, platelets, and the rate of thrombocytopenia were not significantly different between two groups. Conclusion These data suggest that selective head cooling with mild systemic hypothermia in neonates with HIE is safe during 72 h therapy.

Curative Effect Analysis of Mild Hypothermia in Treatment of Neonatal Hypoxic-Ischemic Encephalopathy and Follow-Up Study of 36 Children Aged 18 Months

Safety of selective head cooling with mild systemic hypothermia after neonatal encephalopathy:multicentre randomized trial

Selective Head Cooling with Mild Systemic Hypothermia after Neonatal Hypoxic-Ischemic Encephalopathy: A Multicenter Randomized Controlled Trial in China

[Meta-Analysis of Mild Hypothermia for Gestational Age over 35-Week Newborns with Hypoxic-Ischemic Encephalopathy].

[Efficacy of therapeutic hypothermia on mild neonatal hypoxic-ischemic encephalopathy: a prospective randomized controlled study]

Efficiency Evaluation of Neuroprotection for Therapeutic Hypothermia to Neonatal Hypoxic-Ischemic Encephalopathy.

Safety Study of Hypothermia for Treatment of Hypoxic-Ischemic Brain Damage in Term Neonates

Neural Function Recovery and Safety of Mild Hypothermia Therapy Combined with Monosialotetrahexosylganglioside on Neonatal Asphyxia Complicated by Hypoxic Ischemic Encephalopathy

Early intervention and the prognosis of the neonates with hypoxic ischemic encephalopathy

Influence of the early intervention on mental and psychological development in infants with hypoxic-ischemic encephalopathy

Safety of Selective Head Cooling with Mild Systemic Hypothermia after Neonatal Encephalopathy

Safety of Moderate Hypothermia for Perinatal Hypoxic-Ischemic Encephalopathy: A Meta-analysis.

Hypothermia vs Targeted Normothermia for Neonates With Mild Encephalopathy

Hypothermia combined with neuroprotective adjuvants shortens the duration of hospitalization in infants with hypoxic ischemic encephalopathy: Meta-analysis

Therapeutic hypothermia for neonates with hypoxic-ischaemic encephalopathy in low- and lower-middle-income countries: a systematic review and meta-analysis

Neuroprotection of selective brain hypothermia to neonates with the hypoxic-ischemic brain damage

Research on Safety of Mild Hypothermia Via Selective Head Cooling in Term Neonates with Perinatal Asphyxia

Safety and efficacy of therapeutic hypothermia in neonates with mild hypoxic-ischemic encephalopathy

Study on Follow-Up of Mental and Physical Development for 12 Months Old Infants with Hypoxic-lschemic Encephalopathy

Hypothermia Augments Neuroprotective Activity of Mesenchymal Stem Cells for Neonatal Hypoxic-Ischemic Encephalopathy

Neurodevelopmental evaluation of newborns who underwent hypothermia with a diagnosis of hypoxic ischemic encephalopathy based on the Bayley-III scale